Antibiotics

Genomenon Takes a Leap in the Race to Curate the Genome

Retrieved on: 
Thursday, November 2, 2023
ASHG, Genetic testing, Catalog, WES, Intermountain, Intermountain Health, MD, Software, Society, Genomics, Genome, Mastermind, American Society of Human Genetics, Disease, Risk, WGS, Workflow, Gene, Reasoned action approach, ANN, Patient, Doctor of Philosophy, Diagnosis, Antibiotics, Medical device

ANN ARBOR, Mich., Nov. 2, 2023 /PRNewswire-PRWeb/ -- Genomenon Inc., a leading genomic intelligence company, today announced the first milestone in its journey to curate the human genome with the release of Mastermind 3.0, now including the clinical exome fully curated at the gene level. With this latest launch of its Mastermind Platform, Genomenon is delivering a comprehensive catalog of more than 9,000 gene-disease relationships across 5,500 genes, with more being added each week. These curations, based on ClinGen recommendations, are useful to accelerate novel variant curation, especially in large panels, whole exomes (WES), and whole genomes (WGS). The company is the first to curate the clinical exome at the gene level based on ClinGen guidelines, considered the highest industry standard.

Key Points: 
  • The company is the first to curate the clinical exome at the gene level based on ClinGen guidelines, considered the highest industry standard.
  • As next-generation sequencing technology advances, whole exome and genome testing is quickly replacing less comprehensive methods to identify disease in patients.
  • The latest release of our platform represents a significant milestone in our work to curate the human genome and simplify complex genetic data into actionable insights."
  • Dr. Kiel will also be presenting on November 3, in a session "Understanding Gene-Disease Relationships: A Novel and Actionable Approach".

Jona, a Personalized Health Company Using AI to Analyze the Gut Microbiome, Launches with $5M in Funding

Retrieved on: 
Wednesday, November 1, 2023
GI, Conditional sentence, Science, FDA, Colitis, Intelligence, LLM, Jim Breyer, Crohn's disease, Health, Food, Assistant, Obesity, Pathology, Motivation, Disease, Doctor of Philosophy, NYU Langone Health, Research, Cardiology, Radiology, Medicine, Autoimmune disease, Diet, DSM-IV codes, NIH, AI, Patient, Diagnosis, Parkinson's disease, Longevity, Antibiotics, Medical device, Pharmaceutical industry, LinkedIn

With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health."

Key Points: 
  • With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health."
  • Jona's platform aims to equip these individuals with the latest scientific knowledge to discover root causes and develop effective treatment plans.
  • "Launching this company is a culmination of my lived experiences and a lifelong career in artificial intelligence and healthcare."
  • The first product is an easy at-home microbiome profiling kit that sequences the microbes in an individual's gut microbiome.

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Retrieved on: 
Tuesday, October 31, 2023
NGB, Drug discovery, Doctor of Philosophy, Death, HBI, CDC, ARB, Microbiota, Biobank, Public, FMT, Cancer, Patient, Platform, Antibiotics

WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.

Key Points: 
  • WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.
  • Antibiotic resistance is a growing threat to public health, and new treatments are urgently needed.
  • The New-Generation Biotherapeutic (NGB) drug candidate has the potential to provide a new paradigm in preventing antibiotic-resistant bacteria (ARB) infections.
  • Now, we have predicted fully synthetic microbiome drug composition and our AI-based analysis confirms its efficacy – commented CEO and R&D Director of Human Biome Jaroslaw Bilinski MD, PhD.

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Retrieved on: 
Tuesday, October 31, 2023
NGB, Drug discovery, Doctor of Philosophy, Death, HBI, CDC, ARB, Microbiota, Biobank, Public, FMT, Cancer, Patient, Platform, Antibiotics

WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.

Key Points: 
  • WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.
  • Antibiotic resistance is a growing threat to public health, and new treatments are urgently needed.
  • The New-Generation Biotherapeutic (NGB) drug candidate has the potential to provide a new paradigm in preventing antibiotic-resistant bacteria (ARB) infections.
  • Now, we have predicted fully synthetic microbiome drug composition and our AI-based analysis confirms its efficacy – commented CEO and R&D Director of Human Biome Jaroslaw Bilinski MD, PhD.

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

Retrieved on: 
Tuesday, October 31, 2023
Complete Genomics, ASHG, RNA-Seq, Nebula Genomics, Karkus, G400, Whole genome sequencing, IDT, Medical laboratory, Bio-Rad Laboratories, RNA, University of Massachusetts, Face, Professor, Research, SNP, Society, American Society of Human Genetics, Ecosystem, Partnership, WGS, Human genetics, Google AI, Sequoia, Integrated DNA Technologies, Automation, New England Biolabs, Integration, New England, Completeness, Stanford University School of Medicine, Antibiotics, Medical device, Genomics

At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.

Key Points: 
  • At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.
  • See the full description of speakers Complete Genomics is bringing to ASHG at completegenomics.com/ashg-2023-event-page .
  • Based in San Jose, CA, Complete Genomics celebrated its U.S. commercial launch of its DNBSEQ™ sequencing product line one year ago at ASHG 2022.
  • "Our collaboration with Complete Genomics underscores our commitment to providing researchers with advanced solutions for sequencing applications."

Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, Gene editing, Litopenaeus, US, Disease resistance, Ben-Gurion University of the Negev, Economics, Seafood, CRISPR, RNA, BGU, Computational biology, Research, TASE, IIA, Generator, Israel Innovation Authority, CPO, Macrobrachium, Compound annual growth rate, Aquaculture, Appetite, Antibiotics

HAZEVA and REHOVOT, Israel, Oct. 31, 2023 /PRNewswire/ -- Colors Farm Ltd, a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product discovery and development, today announced a collaboration with Ben-Gurion University (BGU), a renowned Israeli academic research institution, to develop gene editing technology for crustaceans. This synergistic collaboration will focus on crustaceans — specifically targeting giant freshwater prawn (Macrobrachium rosenbergii), white leg shrimp (Litopenaeus vannamei) and red swamp crayfish (Procambarus clarkii), to enhance key traits such as growth rate, disease resistance, and environmental adaptation. The initiative has received a competitive grant from the Israel Innovation Authority (IIA), cementing its role as a pioneering endeavor in the realm of precision agriculture.

Key Points: 
  • Gene editing is a powerful tool that can enhance the economics and sustainability of crustacean production.
  • Ran Epstein, CEO of Colors Farm, emphasized the potential impact of gene editing on crustacean production: "This collaboration represents a major step forward for aquaculture.
  • Gene editing has the power to revolutionize crustacean production, and we are excited to work with Evogene and BGU to turn this potential into reality."
  • "We are pleased to collaborate with Colors Farm and BGU on this significant endeavor" said Nir Arbel, CPO of Evogene: "Through precise modifications of crustacean genomes, gene editing can enhance desired traits and minimize environmental impact.

3 ways to prepare for bushfire season if you have asthma or another lung condition

Retrieved on: 
Thursday, October 26, 2023
People, Smoke, Well, Ozone, Health, Spasm, Nitrogen dioxide, Wheeze, Asthma, Atmosphere, Death, Bronchiectasis, City, Nasal congestion, Particulates, Oxygen, Travel, HEPA, Sulfur dioxide, Burn, Gas, Chronic obstructive pulmonary disease, Emergency, Firewood, Antibiotics, Kerosene, Airline, Hospital, Pharmaceutical industry, Personal protective equipment, Management

This not only affects people in bushfire regions, but those in cities and towns far away, as smoke travels.

Key Points: 
  • This not only affects people in bushfire regions, but those in cities and towns far away, as smoke travels.
  • But after early heatwaves and bushfires, this year may be different
    What’s so dangerous about bushfire smoke?
  • Bushfire smoke pollutes the air we breathe by increasing the concentration of particulate matter (or PM).
  • If you have asthma, chronic obstructive pulmonary disease, bronchiectasis or another lung condition, or you care for someone who has, here’s what you can do to prepare for the season ahead.

mbiomics Appoints Seasoned Microbiome Expert Christopher Weidenmaier as Chief Scientific Officer

Retrieved on: 
Tuesday, October 24, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Principal, Host, Harvard Medical School, CSO, Therapy, Conditional sentence, Doctor of Philosophy, Directorate of Research and Civil Affairs, Division, The German, University, Culture, Infection, Hospital, Coronavirus Scientific Advisory Board, Antibiotics, Microbiology, Hygiene

mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO).

Key Points: 
  • mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO).
  • Dr. Weidenmaier will contribute nearly 20 years of experience in the microbiome and infectious diseases fields and lead the company’s discovery and development efforts as they establish a pipeline of complex microbiome ecosystems product candidates.
  • Over the course of his career, Dr. Weidenmaier has successfully developed and led R&D efforts for next-generation microbiome products.
  • The appointment will strategically expand the mbiomics’ leadership team on its mission to harness the full potential of the microbiome to restore health and overcome disease.

Complete Genomics Partners with Integrated DNA Technologies to Establish New Ecosystem of NGS Products

Retrieved on: 
Wednesday, October 18, 2023
Linda, Complete Genomics, Laboratory, Genomics, IDT, Infection, RNA interference, RNA, CRISPR, PCR, Research, Learning, MGI, NGS, Commercial, Ecosystem, Partnership, Workflow, Integrated DNA Technologies, Synthetic biology, Integration, Marketing, SAN, Completeness, Antibiotics

SAN JOSE, California, Oct. 18, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today announced its partnership with Integrated DNA Technologies (IDT), a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics' innovative DNBSEQ™ sequencing platforms.

Key Points: 
  • SAN JOSE, California, Oct. 18, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today announced its partnership with Integrated DNA Technologies (IDT), a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics' innovative DNBSEQ™ sequencing platforms.
  • Its relationship with MGI, parent company of Complete Genomics, started in June 2018.
  • With Complete Genomics' technical support, IDT has empowered users in library preparation through conversion workflow and data generated by targeted sequencing.
  • With an increasing installation base of DNBSEQ sequencing platforms, the companies are enhancing their partnership by optimizing IDT's technology for Complete Genomics' sequencing platforms.

Persephone Biosciences and Ginkgo Bioworks Complete Reusable Bacteroides Anaerobic Engineering Toolkit

Retrieved on: 
Tuesday, October 17, 2023
Health, NYSE, Biology, Cell engineering, DNA, Therapy, Persephone, Environment, Bacteroides, SAN, Software, Commercial, Medical imaging, Antibiotics, Ginkgo

SAN DIEGO and BOSTON, Oct. 17, 2023 /PRNewswire/ -- Persephone Biosciences Inc., a synthetic biology company reimagining patient health through the microbiome, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of their first collaboration together, a Bacteroides engineering toolkit. Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit. Persephone will utilize the technology to develop a pipeline of microbiome therapeutics, and Ginkgo can use the technology as part of its broader platform offering for future customers.

Key Points: 
  • Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit.
  • Persephone will utilize the technology to develop a pipeline of microbiome therapeutics, and Ginkgo can use the technology as part of its broader platform offering for future customers.
  • The technology comprises a set of generalizable genetic tools which can facilitate rapid Bacteroides engineering, including in the high-throughput anaerobic engineering context.
  • Over the course of this collaboration, Ginkgo incorporated its flagship hardware and software workflows under an anaerobic blanket, meaningfully extending its cell engineering platform capabilities to perform productively in an anaerobic environment.